FDA Approves Eli Lilly’s Kisunla For Treatment Of Early Symptomatic Alzheimer’s Disease

The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Kisunla is administered as an intravenous infusion every four weeks. The medication is intended for people with mild cognitive impairment or the mild dementia stage of the disease.

Coverage and reimbursement for Kisunla are now available for eligible patients on Medicare under a National Coverage Determination with Coverage with Evidence Development. Also, as of October 2023, broad coverage and reimbursement for amyloid positron emission tomography (PET) scans are available for eligible Medicare beneficiaries.

To help people navigate . . .